scholarly journals Crescentic glomerulonephritis associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration

2011 ◽  
Vol 26 (5) ◽  
pp. 1742-1745 ◽  
Author(s):  
K. Stylianou ◽  
E. Lioudaki ◽  
E. Papadimitraki ◽  
G. Kokologiannakis ◽  
N. Kroustalakis ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Crescentic Glomerulonephritis ◽  
Vascular Endothelial ◽  
Vegf Inhibitor ◽  
Endothelial Growth Factor

Crescentic glomerulonephritis induced by anti‐vascular endothelial growth factor receptor 2 antibody

Nephrology ◽  
2021 ◽  
Author(s):  
Taro Horino ◽  
Satoshi Inotani ◽  
Tsunehiro Ochi ◽  
Masayuki Ishihara ◽  
Kenichi Yagyu ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Crescentic Glomerulonephritis ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

Treatment of Coates retinitis in both eyes in a 5-year-old girl

2021 ◽  
pp. 63-65
Author(s):  
A.O. Nazarenko ◽  
◽  
E.E. Sidorenko ◽  
I.V. Suhanova ◽  
A.R. Shavaleeva ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Retinal Detachment ◽  
Clinical Case ◽  
Vascular Endothelial ◽  
Vegf Inhibitor ◽  
Vascular Activity ◽  
Factor Inhibitor ◽  
The Right ◽  
Endothelial Growth Factor

Purpose. To present a rare clinical case of bilateral Coates retinitis in a 5-year-old girl. Material and methods. A clinical case of a 5-year-old girl with rare Coat's retinitis in both eyes is described. The disease occurred abruptly: the child's parents noted the appearance of leukocoria in the right eye. After the examination Coates ' retinitis was diagnosed. At the time of examination in the clinic, there was a retinal detachment in the right eye, the surgical treatment was performed: lensvitrshvartectomy, plastic surgery of the anterior chamber, with the melting of the retina with perfluoroorganic compounds, drainage of subretinalfluid, endolaser coagulation on the right eye. A month after the first symptoms appeared in the right eye, the patient complained of decreased vision in the left eye. Examination on the pediatric retinal camera showed an increase in vascular activity in the left eye, and signs of Coats' retinitis were revealed. Results. As a therapy for this disease, the patient was twice injected intravitreally inhibitor of vascular endothelial growth factor (VEGF inhibitor) into the left eye with positive dynamics noted as a decrease in the activity of retinal vessels and leveling of the exudative component, as well as with an increase in visual acuity in the left eye. Conclusion. This clinical case demonstrates that intravitreal administration of inhibitor VEGF with traditional methods of treatment can be used as a treatment for patients with Coates retinitis. Key words: Coat's retinitis, Coats' disease, vascular endothelial growth factor inhibitor, aflibercept, intravitreal injection, anti-VEGF, retinal detachment.

Intravitreous Vascular Endothelial Growth Factor (VEGF) Inhibitor Therapy for Tamoxifen Induced Macular Edema

2007 ◽  
Vol 22 (2) ◽  
pp. 87-88 ◽  
Author(s):  
Dan H. Bourla ◽  
Christine R. Gonzales ◽  
Charles W. Mango ◽  
Joel N. Moral ◽  
Robert S. Wirthlin ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Macular Edema ◽  
Inhibitor Therapy ◽  
Vascular Endothelial ◽  
Vegf Inhibitor ◽  
Endothelial Growth Factor

Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGF-i) following stereotactic body radiotherapy (SBRT).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e14507-e14507
Author(s):  
Brandon M. Barney ◽  
Svetomir Markovic ◽  
Nadia N. Laack ◽  
Robert C. Miller ◽  
Jann Nagina Sarkaria ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Stereotactic Body Radiotherapy ◽  
Rank Test ◽  
Vegf Receptor ◽  
Vascular Endothelial ◽  
Vegf Inhibitor ◽  
Factor Inhibitor ◽  
Grade 3 ◽  
Endothelial Growth Factor

e14507 Background: Serious gastrointestinal injury (SGI) is a rare but documented side effect that can occur independently with agents that affect the vascular endothelial growth factor (VEGF) receptor or with stereotactic body radiotherapy (SBRT). The risk of SGI in patients treated with the combination of SBRT sequentially followed by a VEGF inhibitor (VEGF-i) is not yet quantified. We explored the incidence of SGI in patients treated with SBRT with or without VEGF-i therapy at a single institution. Methods: From May 2008 to August 2011, 76 patients with 84 primary or metastatic intraabdominal lesions underwent SBRT (median dose, 50 Gy in 5 fractions). Twenty of these patients (26%) received a VEGF-i within two years of completing SBRT (bevacizumab, n=14; sorafenib, n=4; pazopanib, n=1; sunitinib, n=1). The most common site treated with SBRT was the liver (n=43, 57%), and the most common histology was colorectal adenocarcinoma (n=18, 24%). Other common histologies included melanoma of the skin (n=14, 18%) and non-small cell lung cancer (n=10, 13%). The incidence of SGI (CTCAE v4.0 grade 3 to 5 ulceration or perforation) after SBRT was obtained, and the relationship between SGI and VEGF-i was examined. Other factors that could potentially contribute to SGI, such as radiotherapy dose to bowel, were also analyzed. Results: Seven patients (9%) experienced SGI at a median 4.6 months (range, 3-17 months) after SBRT. All seven had received a VEGF-i prior to SGI and within 13 months of completing SBRT, and five received the VEGF-i within three months of SBRT. The six-month estimate of SGI in patients receiving a VEGF-i within three months of SBRT was 38%. No SGI was noted in the 63 patients not receiving VEGF-i therapy after SBRT. The Log-Rank test showed a significant correlation between SGI and VEGF-i therapy within three months of SBRT (p=0.0006) but not between SGI and maximum radiotherapy bowel dose (p=0.20). Conclusions: The combination of SBRT and VEGF-i therapy results in a much higher risk of SGI than would be expected with either treatment given independently. Local therapies other than SBRT should be considered if a patient is likely to be treated with a VEGF-i in the future.

Intravitreal vascular endothelial growth factor (VEGF) inhibitor injection in unrecognised early pregnancy

2016 ◽  
Vol 34 (5) ◽  
pp. 650-653 ◽  
Author(s):  
Farzan Kianersi ◽  
Heshmatollah Ghanbari ◽  
Zahra Naderi Beni ◽  
Afsaneh Naderi Beni
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Early Pregnancy ◽  
Vascular Endothelial ◽  
Vegf Inhibitor ◽  
Endothelial Growth Factor

scholarly journals Early experience of vascular endothelial growth factor (VEGF) inhibitor in COVID-19 ARDS

2021 ◽  
Vol 89 (6) ◽  
pp. 618-620
Author(s):  
Vikas Marwah ◽  
Robin Choudhary ◽  
Tentu Ajai Kumar ◽  
Deepu Peter
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Early Experience ◽  
Vascular Endothelial ◽  
Vegf Inhibitor ◽  
Endothelial Growth Factor
Sign in / Sign up

Export Citation Format

Share Document